Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis.

Abstract

PURPOSE Mac-2 binding protein (Mac-2 bp) is one of the major fucosylated glycoproteins, which we identified with glycol-proteomic analyses. We previously reported that fucosylated glycoproteins are secreted into bile, but scarcely secreted into sera in normal liver and hypothesized that the fucosylation-based sorting machinery would be disrupted in ballooning hepatocytes due to the loss of cellular polarity. In the present study, we investigated the availability of Mac-2 bp for differential diagnosis of nonalcoholic steatohepatitis (NASH) from nonalcoholic fatty liver disease (NAFLD) as a biomarker. EXPERIMENTAL DESIGN Serum Mac-2 bp levels were determined with our developed ELISA kit. Our cohort of 127 patients with NAFLD had liver biopsy to make a histological diagnosis of NASH and simple fatty liver. RESULTS Mac-2 bp levels were significantly elevated in NASH patients compared with non-NASH (simple steatosis) patients (2.132 ± 1.237 vs. 1.103 ± 0.500 μg/mL, p < 0.01). The area under the receiver-operating characteristic curve for predicting NASH by Mac-2 bp was 0.816. Moreover, multivariate logistic regression analyses showed Mac-2 bp levels could predict the fibrosis stage and the presence of ballooning hepatocytes in NAFLD patients. CONCLUSIONS AND CLINICAL RELEVANCE These results support the potential usefulness of measuring Mac-2 bp levels in clinical practice as a biomarker for NASH.

DOI: 10.1002/prca.201200137
02004002014201520162017
Citations per Year

553 Citations

Semantic Scholar estimates that this publication has 553 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Kamada2013SerumMB, title={Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis.}, author={Yoshihiro Kamada and Hideki Fujii and Hironobu Fujii and Yoshiyuki Sawai and Yoshinori Doi and Naofumi Uozumi and Kayo Mizutani and Maaya Akita and Motoya Sato and Sachiho Kida and Noriaki Kinoshita and Nobuhiro Maruyama and Takayuki Yakushijin and Masanori Miyazaki and Hisao Ezaki and Naoki Hiramatsu and Yuichi Yoshida and Shinichi Kiso and Yasuharu Imai and Norifumi Kawada and Tetsuo Takehara and Eiji Miyoshi}, journal={Proteomics. Clinical applications}, year={2013}, volume={7 9-10}, pages={648-56} }